Enzolytics Inc (ENZC)

[29YEARINVESTOR]

We EXPECT the ... SAME RESULTS as the BULGARIAN TRIALS
Patients were Stage II, III and late stage IV! Go ENZC

The prior clinical trial showed an 80% drop in viral load, an increase in CD4+ cell counts as well as an increase in other key immune cells. CD4+ cells are the cells that are infected by HIV and are eventually depleted by the virus. So the increase in CD4 count is key. For instance, this could include dendritic cells, macrophages, monocytes, and helper T cells. And in line with the improved cell counts were improvements in opportunistic infections, compatibility with other ART (antiretroviral therapy) drugs, and no side effects.

The big difference to keep in mind is that all the currently marketed drugs use chemotherapy versus immunotherapy. None of the current drugs help restore the immune system. They simply block the viral replication inside the immune cells.